Cancer Research UK

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. With over 150 pharma services/supply companies and 19 universities, Scotland is one of the most advanced life science sectors in the UK and the world. To demonstrate how Scotland is continuing to innovate and shape […]

Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The collaboration focuses on the development of two investigational antibody candidates, UCB6114 and UCB4594, by bringing together the oncology-focused translational research and clinical development capabilities of Cancer Research UK, and UCB’s antibody […]

Cancer Research UK, The University of Manchester and Roche have opened a multi-drug, precision medicine trial for people with rare cancers.  The trial is set up to recruit both paediatric and adult patients with any rare cancer type and is one of very few precision medicine platform trials in the world targeting these populations.  The […]

Cancer Research UK’s innovation engine, Cancer Research Horizons, and Newcastle University, have agreed an extension of their strategic drug discovery alliance with Astex Pharmaceuticals.  The alliance will continue to focus on the discovery of potential new cancer drugs with associated biomarkers, with the aim of providing an innovative route to the development of more effective […]

Ahead of the UK Government’s Autumn Statement on Thursday, leading biomedical research companies, charities and institutions have called for the Chancellor to place medical and health research at the heart of plans for growth.  The letter has been signed by the Academy of Medical Sciences, Pfizer, Wellcome, the BioIndustry Association, and Cancer Research UK, amongst […]

Scientists have shown how stomach cancers can develop resistance to a new class of drugs called ATR inhibitors by switching off the activity of two key genes – raising the possibility of outsmarting cancer by predicting drug resistance in advance.  The findings could pave the way for a genetic test to predict which patients are […]

Earlier this year, Cancer Research UK (CRUK) launched its innovation engine, Cancer Research Horizons, to streamline drug discovery through the combination of its commercial and therapeutics teams. Reece Armstrong sits down with Cancer Research Horizons’ Chief Business Officer, Tony Hickson and CEO of its Therapeutics division, Hamish Ryder, to learn about the organisation’s goals.  RA: […]

Cancer Research UK has formed a strategic alliance with a research institute in the Netherlands as part of a joint effort to boost understanding into cancer and to translate research in patient benefits.   Cancer Research UK will work with the Stichting Oncode Institute in the Netherlands on a five-year partnership to foster innovation and collaboration […]